SYRS Syros Pharmaceuticals: צמיחת הכנסות רבעונית

Syros Pharmaceuticals (SYRS) is currently undergoing a rigorous debt restructuring process and seeking buyers for its patents. The operating model is based on the full outsourcing of clinical phases to third-party contractors. Quarterly revenue changes on the GURU.Markets terminal chart confirm this decline, with the metric holding around 0.00, highlighting the company's focus on the development of tamibarotene for leukemia therapy.
פילוחי נתונים אנליטיים מרוכזים עבור Syros (SYRS)

For Syros Pharmaceuticals (SYRS), which is developing targeted leukemia therapies, quarterly revenue growth statistics serve as an indicator of drug commercialization during the clinical trial stage. This metric measures the percentage change in revenue between the current and previous quarter, allowing investors to use the chart's price action to identify a hidden slowdown in cash flows before it becomes evident in annual reports.